We focus on innovative treatments for patients suffering from neurological, neuromuscular and ophthalmic diseases. Our first product candidates in development target primary optical atrophy. We are further evaluating them for use in serious neurological / neuromuscular diseases such as ALS, Huntington's, Alzheimer’s and Parkinson’s disease.
Our team is composed of passionate and innovative founders and experts who have solid track records in drug development and clinical research in multinational pharmaceutical companies or management experience in international technology enterprises. Their determination in bringing life-changing treatments to patients encompasses everything they do.